Showing results (201-210 of 258) with videos related to

Sort By:
Pageof 26
The Lancet. Oncology|March 29, 2012
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialJames Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, et al.
Journal of Biomedical Science|February 5, 2016
Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibilityShi-Yi Yang, Chia-Ni Hsiung, Yao-Jen Li, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
The New England Journal of Medicine|June 5, 2023
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.
The New England Journal of Medicine|April 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerPasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
Frontiers in Oncology|October 11, 2021
Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-SmokersSheng-Kai Liang, Li-Hsin Chien, Gee-Chen Chang, et al.
Scientific Reports|March 1, 2022
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapyPo-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, et al.
The Lancet. Respiratory Medicine|October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyMyung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.
Pageof 26